SOMERSET, N.J.--(BUSINESS WIRE)--Catalent Pharma Solutions announces the recent successful completion of the first FDA general cGMP audit and pre-approval inspection of its Buenos Aires, Argentina pharmaceutical softgel facility, with no reported observations on FDA Form 483. Catalent has been operating in Argentina since 1953 serving local and regional pharmaceutical and consumer health markets, and is completing a substantial expansion of the facility designed to meet FDA and other global regulatory standards.
